Medtech Fraud Part II: Claims from an Investor Perspective
In the first instalment of this series, we looked at the state of the MedTech sector, the capital being poured into it and how and why those circumstances – brought into even sharper relief by the Covid-19 pandemic – appear primed to give rise to feelings of buyer’s remorse. In this instalment, CYK partner Sam Roberts, looks at […]